Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

out the merger. The proxy statement and other relevant materials, and any other documents filed by SGX with the SEC, may be obtained free of charge at the SEC's website at http://www.sec.gov. In addition, investors and stockholders may obtain free copies of the documents filed with the SEC by going to SGX's Investor Relations page on its corporate website at http://www.sgxpharma.com or by directing a written request to SGX at 10505 Roselle Street, San Diego, California 92121 -- Attention: Corporate Secretary.

Participants in the Solicitation

SGX and its directors and executive officers may be deemed to be participants in the solicitation of proxies from SGX stockholders in connection with the merger. Certain directors and executive officers of SGX may have direct or indirect interests in the merger due to, among other things, securities holdings, pre-existing or future indemnification arrangements, vesting of equity awards, or rights to severance payments in connection with the merger. Additional information regarding the directors and executive officers of SGX and their interests in the merger is contained in the definitive proxy statement that SGX filed with the SEC.

Forward Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to research and development programs, the proposed merger transaction, including whether the merger transaction will be approved by SGX's stockholders, whether the other conditions to closing of the proposed transaction will be met and if any of the potential benefits of the proposed merger will be realized, the potential of the Company's inhibitors as treatments for certain cancers, and the ability to discover, develop, build a pipeline of and commercialize cancer therapeuti
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... , March 30, 2015 ... novel biological drugs to treat cancer, viral infections ... Professor Sir John Bell , the Regius ... of the Office for the Strategic Coordination of ... immediate effect.      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ...
(Date:3/30/2015)... MADISON, Wis. , March 30, 2015 ... (TSE: 4901) ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: ... ("CDI"), a leading developer and manufacturer of fully functioning ... announced that the two companies have entered into a ... all-cash tender offer to be followed by a second ...
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 ... the presentation of important study data showing ... cells in 1,599 gynecologic cancer samples. Using ... tumor profiling service, researchers identified expression of ... gynecologic cancers independent of histology while its ...
Breaking Biology Technology:Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4
... PARIS and PRINCETON, New Jersey, March 5 , ... Early Use of,Plavix(R) by Simplifying Administration in Acute Coronary ... and Bristol-Myers Squibb,Company (NYSE: BMY ) announced today ... of the European Medicines Evaluation Agency,(EMEA) has issued a ...
... FREMONT, Calif., March 4 Vermillion, Inc.,(Nasdaq: ... recent,accomplishments across its diagnostic test programs and provided ... achieve over the course of 2008. The,Company also ... year,ended December 31, 2007., "In 2007, Vermillion ...
... Board of Directors of,Bristol-Myers Squibb Company (NYSE: BMY ) ... on the $.10 par value Common,Stock of the corporation. The ... of record at the close of business on April 4, ... fifty cents ($0.50),per share on the $2.00 Convertible Preferred Stock ...
Cached Biology Technology:New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 2New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 3New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 2Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 3Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 5Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 6Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 7Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 8Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 9
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
(Date:3/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing ... wallet has been named the "Number One Best ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a ... home and lifestyle that have a unique function or ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... has long been used topically in many skin creams ... for the skin. Now, new research just published in ... consuming flavanol-rich cocoa and how it might actually benefit ... certain components in cocoa may actually help improve the ...
... vaccines may increase elderly patients' immune response without ... protection against the flu, according to an article ... Internal Medicine, one of the JAMA/Archives journals. , ... for 50 years to prevent flu and its ...
... the Stanford University School of Medicine have taken a ... that could eventually be transplanted into living organisms. , ... resident Oscar Abilez, MD, and colleagues have successfully differentiated ... blocks of blood vessels, after placing them in a ...
Cached Biology News:New study reveals components of cocoa may enhance the appearance of the skin 2High-dose flu vaccines appear to safely boost immunity in elderly 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 3
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
... HT, 1 kit. Facilitates the simple, phenol-free ... and hard tissue requiring proteinase K digestion.Each ... DNA from 50 preparations of up to ... Synthesis & Purification, Purification and Amplification of ...
Request Info...
Ultra-sensitive, non-radioactive measurement of COX-I and COX-II activity...
Biology Products: